National Foundation for Cancer Research
VC Fund
Bethesda, United States
National Foundation for Cancer Research is a group of researchers on the cutting edge of cancer discoveries and developments.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries National Foundation for Cancer Research invests in
Stages National Foundation for Cancer Research invests in
Countries National Foundation for Cancer Research invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sreekumar Raghavakaimal
|
|||
Investment Focus
Industry
- Biotechnology 4 (100%)
- Health Care 2 (50%)
- Life Science 2 (50%)
- Pharmaceutical 2 (50%)
- Medical 1 (25%)
Stage
- Seed 1 (25%)
- Grant 1 (25%)
- Series A 1 (25%)
- Funding Round 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sreekumar Raghavakaimal
Senior Vice President & Chief Development Officer
|
Senior Vice President & Chief Development Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Acurion
|
Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $4.3M / Seed / Apr 02, 2026 | |
SciTech Development
|
SciTech Development is a specialty pharmaceutical company focusing on cancer treatments. It has developed a Drug Delivery Platform (SDP) that enables scientists to engineer, develop, and patent new drugs. Its first, patented drug candidate, ST-001-nanoFenretinide combines SDP and the promising drug fenretinide as a broadly applicable anticancerdrug. | $2.7M / Jun 07, 2023 | |
TellBio
|
TellBio is a provider of biotechnology service. | $5M / Series A / Mar 16, 2021 | |
Rasio Therapeutics
|
Rasio Therapeutics is a biopharmaceutical company that develops novel medicines using computer-aided drug design technology. Its core strategy is to keep overhead and infrastructure costs low while accelerating the ability to trigger liquidity events. With this model, they are running multiple drug discovery and development programs in parallel.It aims to address unmet patient needs through modeling of novel/deep cell-binding regions. Rasio designs molecules to fit those regions and enhance treatment for cancer and other diseases. The company was founded in 2019 and is based in Baltimore, Maryland. | $1M / Grant / Nov 25, 2019 |
Co-Investors
ARUP Laboratories
1 deal together
Asian Fund For Cancer Research
1 deal together
Bootstrap Venture Partners
1 deal together
Crocker Ventures
1 deal together
Genetron Health
1 deal together
HRM
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does National Foundation for Cancer Research invest in?
National Foundation for Cancer Research invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Grant stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact National Foundation for Cancer Research?
Public channels for National Foundation for Cancer Research include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at National Foundation for Cancer Research?
The team at National Foundation for Cancer Research includes Sreekumar Raghavakaimal (Senior Vice President & Chief Development Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
